Ashraf S Ibrahim, Guanpingsheng Luo, Teclegiorgis Gebremariam, Hongkyu Lee, Clint S Schmidt, John P Hennessey, Samuel W French, Michael R Yeaman, Scott G Filler, John E Edwards
We have previously reported that vaccination with rAls3p-N protein of Candida albicans, formulated with alum adjuvant (also designated as NDV-3) protects immunocompetent mice from, lethal disseminated candidiasis and mucosal oropharyngeal candidiasis. NDV-3 vaccine was recently, tested in a Phase 1 clinical trial and found to be safe, well-tolerated, and induced robust humoral and, cellular immune responses with increased interferon (IFN)-gamma and interleukin (IL)-17 secretion. In preparation for a Phase 2 clinical trial against vulvovaginal candidiasis (VVC), we evaluated NDV-3, efficacy in a murine VVC model...
November 12, 2013: Vaccine